| Acute bacterial skin and skin structure infection
Kimyrsa vs Orbactiv
Side-by-side clinical, coverage, and cost comparison for acute bacterial skin and skin structure infection.Deep comparison between: Kimyrsa vs Orbactiv with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrbactiv has a higher rate of injection site reactions vs Kimyrsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orbactiv but not Kimyrsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kimyrsa
Orbactiv
At A Glance
IV infusion
Single dose
Lipoglycopeptide antibacterial
IV infusion
Single dose
Lipoglycopeptide antibacterial
Indications
- Acute bacterial skin and skin structure infection
- Acute bacterial skin and skin structure infection
Dosing
Acute bacterial skin and skin structure infection 1,200 mg as a single dose by intravenous infusion over 1 hour in patients 18 years and older.
Acute bacterial skin and skin structure infection 1,200 mg as a single dose by IV infusion over 3 hours in patients 18 years and older.
Contraindications
- Use of intravenous unfractionated heparin sodium for 120 hours (5 days) after KIMYRSA administration due to false aPTT elevation
- Known hypersensitivity to oritavancin products
- Concomitant use of intravenous unfractionated heparin sodium within 120 hours (5 days) after ORBACTIV administration due to falsely elevated aPTT test results
- Known hypersensitivity to oritavancin products
Adverse Reactions
Most common (>=3%) Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea
Serious Cellulitis, osteomyelitis, hypersensitivity reactions, infusion related reactions, Clostridioides difficile-associated diarrhea
Most common (>=3%) Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea.
Serious Cellulitis, hypersensitivity reactions, infusion-related reactions, Clostridioides difficile-associated diarrhea, osteomyelitis.
Pharmacology
Oritavancin is a semisynthetic lipoglycopeptide antibacterial that exerts concentration-dependent bactericidal activity via three mechanisms: inhibition of cell wall transglycosylation and transpeptidation steps, and disruption of bacterial membrane integrity, active against Gram-positive organisms including methicillin-resistant S. aureus.
Oritavancin is a semisynthetic lipoglycopeptide antibacterial that inhibits transglycosylation and transpeptidation steps of cell wall biosynthesis and disrupts bacterial membrane integrity, producing concentration-dependent bactericidal activity against susceptible Gram-positive organisms; antimicrobial activity correlates with the AUC/MIC ratio.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kimyrsa
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Orbactiv
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Kimyrsa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Orbactiv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kimyrsa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Orbactiv
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/fillfill
Kimyrsa Copay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$50/fillfill
Orbactiv Copay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KimyrsaView full Kimyrsa profile
OrbactivView full Orbactiv profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.